Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Qiagen ( (QGEN) ).
Qiagen N.V. has been informed by the Netherlands Authority for the Financial Markets (AFM) about a notification regarding a significant transaction involving Massachusetts Financial Services Company. The transaction, which took place on December 4, 2025, involves a substantial holding in Qiagen’s ordinary shares, with a total capital interest of 7.78% and voting rights of 10.04%. This development highlights the strategic interest of major financial institutions in Qiagen, potentially impacting its market positioning and stakeholder dynamics.
The most recent analyst rating on (QGEN) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products and services that enable customers to gain valuable insights from biological samples.
Average Trading Volume: 1,172,126
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.88B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.